Survey of oncologists finds knowledge gap on medical marijuana

June 18, 2018 by Alvin Powell, Harvard University
Almost half of the cancer doctors surveyed by Harvard psychiatrist Ilana Braun said they recommend medical marijuana to patients while less than a third said they felt knowledgable enough to do so. Credit: Kris Snibbe/Harvard Staff Photographer

As more states legalize medical marijuana, two key groups—researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users—are struggling to catch up with policymakers.

Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial oncology at the Dana-Farber Cancer Institute, led a survey of cancer physicians around the country, exploring their attitudes and actions on .

The survey was sent to 200 oncologists, with a 63 percent response rate. We asked Braun to outline her findings, which were published last month in the Journal of Clinical Oncology.

GAZETTE: What are the highlights of the survey?

BRAUN: I think the key messages from the data are, first of all, though almost half of oncologists surveyed recommend medical marijuana clinically, less than a third feel equipped with enough knowledge to make such recommendations.

Our second key message is that medical marijuana is a salient topic in today's cancer care. Eighty percent of oncologists we surveyed hold discussions with patients about medical marijuana. Sixty-seven percent believe it to be useful as an adjunct to standard pain management, and 68 percent for poor appetite cachexia [illness-related weight loss and frailty].

The third key message is that there are some nonmedical variables that affect how oncologists approach medical marijuana, and these include region of practice, practice setting, and the number of patients they see.

GAZETTE: So a significant percentage of oncologists who recommend medical marijuana to their patients also say they didn't feel knowledgeable enough to do so. How do we make sense of that? I assume it's not as simple as these folks being bad doctors.

BRAUN: Right, and I don't want to imply that. Unfortunately, our survey wasn't designed to drill down into why this might be the case, but it's definitely curious and we need to explore more.

GAZETTE: Is this an education problem or a research problem?

BRAUN: I think it's probably a little bit of both. There isn't a lot of high-quality research done in oncology regarding medical marijuana. So we probably need some clinical-effectiveness trials involving medical marijuana in oncology—and in other illnesses—and then I think we probably need more research in how to best inform medical professionals, particularly oncologists, who are frequently confronted with this issue.

GAZETTE: How do physicians, once they become licensed and go out into practice, keep up on recent developments like the advent of medical marijuana?

BRAUN: That's a good question. We all take it upon ourselves to read scientific literature that comes out. We have journals like the New England Journal of Medicine, or our specialty journals. We try to read those. Then we're obligated by licensing bodies to complete continuing medical education credits, otherwise known as CMEs. In that context, we go to national conferences or do online modules, so we are constantly trying to broaden our knowledge and keep current. And then many of us are obligated to retest at regular intervals, let's say every 10 years.

GAZETTE: Do we know whether there are CMEs specifically about medical marijuana?

BRAUN: There certainly are. I believe that in the state of New York, in order to become a physician who can formally recommend medical marijuana to patients, you need to complete a four-hour CME requirement. It's a state-organized curriculum. In Massachusetts, you have to complete two of what we call level 1 CMEs on medical marijuana, so a two-hour course.

GAZETTE: What do we know about the medical benefits of marijuana, for pain, nausea, anxiety—some of these conditions that it's potentially useful for?

BRAUN: Randomized control trials of whole-plant medical marijuana haven't been carried out in cancer patients, so oncology often draws from evidence in clinical trials carried out on other diseases and also from clinical trials carried out with pharmaceutical cannabinoids [the active compounds in marijuana]. Maybe pharmaceutical cannabinoids have one active ingredient, or two active ingredients—they may be synthetic, they may be herb-derived—but it's different from marijuana. We extrapolate from those.

In that context, the indication that probably has the strongest evidence base is pain. There have been more than half a dozen good, randomized control trials of whole-plant medical marijuana for pain management.

GAZETTE: And they showed that it's effective?

BRAUN: They showed that it's effective. And there are FDA-approved cannabinoid pharmaceuticals that you can get at the pharmacy, dronabinol being one of them. It's FDA-approved for weight-loss cachexia. I'm sure oncologists are extrapolating from their knowledge of this drug that they use all the time in the clinic.

GAZETTE: Why is it important that the usefulness of medical marijuana be tested specifically in an oncology setting?

BRAUN: Other studies are usually done in very specific populations. It's not clear you can generalize them to another disease.

GAZETTE: Without the studies that you believe are still needed, is marijuana legalization premature?

BRAUN: It's a complex issue. Something like 30 states and the District of Columbia have comprehensive medical marijuana laws, and then many additional states have less-comprehensive but still some form of medical marijuana. Given that these medical marijuana laws are so popular on a state level, I think that we need to catch up with the science.

GAZETTE: Why did you do this study?

BRAUN: I worked clinically with cancer patients and found that the topic of medical marijuana comes up frequently in the exam room.

Second, 30 states and the District of Columbia have these comprehensive , and the vast majority name cancer as a qualifying condition. Very few other conditions exist in almost every state law—cancer and HIV/AIDS—and yet the views of oncologists regarding medical had not been explored. So I thought this was a hole in the literature that should be plugged.

Explore further: Many oncologists recommend medical marijuana clinically despite not feeling sufficiently knowledgeable to do so

Related Stories

Many oncologists recommend medical marijuana clinically despite not feeling sufficiently knowledgeable to do so

May 10, 2018
While a wide majority of oncologists do not feel informed enough about medical marijuana's utility to make clinical recommendations, most do in fact conduct discussions on medical marijuana in the clinic and nearly half recommend ...

How can medical marijuana benefit older adults?

April 19, 2018
Managing symptoms such as pain, nausea, and psychiatric illness can be challenging as people age. A new Journal of the American Geriatrics Society review highlights what's currently known about the indications and risks of ...

Marijuana legalization may reduce opioid use

April 4, 2018
(HealthDay)—State implementation of medical marijuana laws is associated with a reduction in the rate of opioid prescribing, according to a study published online April 2 in JAMA Internal Medicine.

Medical marijuana for children with cancer? What providers think

December 12, 2017
A study published in Pediatrics examined interdisciplinary provider perspectives on legal medical marijuana use in children with cancer. It found that 92 percent of providers were willing to help children with cancer access ...

Debunking claims about medical marijuana

February 22, 2018
In 1996, California became the first US state to legalise marijuana use for medical purposes. Medical marijuana is now legal in 29 states. Opponents of medical marijuana argue that such laws increase recreational marijuana ...

Survey: Medical marijuana could reduce opioid use in older adults

May 1, 2018
A questionnaire of older men and women suffering from chronic pain who were given medical marijuana found that the drug significantly reduced pain and their need for opioid painkillers, Northwell Health researchers report.

Recommended for you

It's not just for kids—even adults appear to benefit from a regular bedtime

September 21, 2018
Sufficient sleep has been proven to help keep the body healthy and the mind sharp. But it's not just an issue of logging at least seven hours of Z's.

Most nations falling short of UN targets to cut premature deaths from chronic diseases

September 21, 2018
People in the UK, US and China have a higher risk of dying early from conditions like cancer, heart disease and stroke than people in Italy, France, South Korea and Australia.

Patient-centered visual aid helps physicians discuss risks, treatments with parents

September 21, 2018
A series of illustrations and charts designed as decision aids for parents of children with minor head injuries helped them communicate with emergency medicine physicians and make informed decisions about their child's care, ...

Alcohol responsible for one in 20 deaths worldwide: WHO

September 21, 2018
Alcohol kills three million people worldwide each year—more than AIDS, violence and road accidents combined, the World Health Organization said Friday, adding that men are particularly at risk.

Smart pills dumb down medical care, experts warn

September 21, 2018
Enthusiasm for an emerging digital health tool, the smart pill, is on the rise but researchers at the University of Illinois at Chicago have published a paper in the American Journal of Bioethics that cautions health care ...

China's doctor shortage prompts rush for AI health care

September 20, 2018
Qu Jianguo, 64, had a futuristic medical visit in Shanghai as he put his wrist through an automated pulse-taking machine and received the result within two minutes on a mobile phone—without a doctor present.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.